HealthTech

Hims & Hers Health Q2 2026 earnings and financial results, showing the company amid record revenue growth, international expansion following the Eucalyptus acquisition, weight loss and GLP-1 business changes, and mounting legal and regulatory risk from the FTC privacy lawsuit.

Hims & Hers Posts Record Revenue Amid Mounting Legal Risk

A 38 percent revenue surge and rapid global expansion collided with a surprise net loss, a new legal reserve, and an unresolved FTC privacy lawsuit in the second quarter of 2026.

Tech IconsAug 11, 2026Digital HealthEarnings ReportHealthTech

Scientist holding a laboratory test tube during pharmaceutical research at Novo Nordisk, illustrating Ziltivekimab, ZEUS trial, IL-6 inhibitor research, cardiovascular inflammation therapy, heart disease treatment and clinical drug development.

Novo Nordisk's Ziltivekimab Fails Pivotal Heart Trial

Ziltivekimab reduced cardiovascular inflammation exactly as designed, yet failed to cut heart attacks, strokes, or cardiovascular death, sending Novo Nordisk shares down sharply.

Tech IconsJul 31, 2026BiotechHealthcarePharmaceuticals

Eli Lilly Q1 2026 results reflecting tirzepatide sales surge, Mounjaro and Zepbound growth, and expanding GLP-1 drug market demand

Eli Lilly Posts 56% Revenue Surge as Incretin Empire Expands

Tirzepatide demand, oral GLP-1 approval, and raised full-year guidance confirm Eli Lilly's grip on the world's most consequential pharmaceutical franchise.

Tech IconsApr 30, 2026BiotechDrug DiscoveryPharmaceuticals

Novartis Q1 2026 earnings show Novartis Kisqali growth, Novartis Pluvicto sales, Novartis Entresto decline and Novartis pharma growth across Novartis drug portfolio, Novartis financial results, Novartis revenue and growth, Novartis oncology drugs, Novartis patent expiry impact, Novartis growth brands, Novartis drug sales growth and Novartis pharma strategy

Novartis Q1 2026 Earnings Show Growth Beyond Patent Cliff

Kisqali, Pluvicto, and Kesimpta posted combined growth above 50 percent, signalling that Novartis's post-patent transition is advancing faster than headline numbers suggest.

Tech IconsApr 28, 2026BiotechDrug DevelopmentPharmaceuticals

OpenAI pharmaceutical partnership Novo Nordisk AI drug discovery healthcare AI digital transformation Novo Nordisk OpenAI alliance AI strategy

Novo Nordisk and OpenAI Join Forces to Reshape Drug Discovery

Read more

Woman wearing a Whoop fitness tracker during an ice bath recovery session as Whoop launches its women’s health biomarker panel, integrating wearable data with women’s health biomarkers.

Whoop Launches Women’s Biomarker Panel as Femtech Surges

Read more

Eli Lilly headquarters as weight-loss drugs Mounjaro and Zepbound drive record quarterly revenue

Lilly Delivers Record Q4 as Weight-Loss Drugs Rewrite Economics

Read more

The Strava app displayed on a smartphone, highlighting the platform’s activity tracking and social features ahead of its planned IPO.

Strava Files for IPO at $2.2B Valuation, $500M Revenue

Read more

Becky Quick, CNBC journalist and host, photographed in a studio setting ahead of the CNBC Cures Summit on rare disease research, Becky Quick brings rare disease innovation into focus through CNBC Cures, uniting science, patients and policy to accelerate genetic research.

Becky Quick and CNBC Cures: Advancing Rare Disease Innovation

Read more

President Donald Trump meets pharmaceutical executives at the White House as Medicare pricing reforms set the stage for oral Wegovy’s FDA approval.

Trump Administration Medicare Deal Powers Novo's Oral Rollout

Read more

Novartis global headquarters as the company announces a $1.7 billion AI drug discovery partnership with Relation Therapeutics.

Novartis Commits $1.7 Billion to AI-Driven Drug Discovery

Read more

Novo Nordisk’s public-facing operations now sit at the center of investor scrutiny as patent timelines tighten.

Novo Nordisk Meets a Patent Cliff as GLP-1 Dominance Weakens

Read more

AI Cyberattacks Surge as Deepfakes and ML Breach Defenses

Workday Reports Data Breach Through Third-Party CRM System

Security Flaw in Perplexity's Comet AI Browser Exposes User Data

DDoS Attacks Overwhelm Global Digital Networks via IoT Botnets

AI Tools Turn Hackers Into Sophisticated Cybercrime Threat

Jensen Huang, Nvidia CEO, as Nvidia expands its role in AI infrastructure financing through partnerships with six major asset managers aimed at mobilizing more than $500 billion in capital for AI compute, data centers and next-generation infrastructure.

Nvidia Turns Its GPUs Into a $500 Billion Asset Class

Read more

Uber to Acquire Delivery Hero in $14.8 Billion Food Delivery Deal

Read more

Hand holding a smartphone displaying the PayPal app as Stripe and Advent proposed a PayPal acquisition, highlighting digital payments, fintech, stablecoin payments, and the payments industry.

Stripe, Advent Offer $53 Billion to Buy PayPal Holdings

Read more